Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
for Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Drug: Bevacizumab
604 locations incl. Anchorage
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04181060·Phase 3·Recruiting